BIOSISTEMIKA, RAZISKAVE IN RAZVOJ DOO

Their core work

Biosistemika is a Slovenian biotech SME specializing in molecular diagnostics, bioinformatics, and DNA-based data storage technologies. They develop high-throughput robotic platforms and diagnostic tools for detecting plant viruses and respiratory pathogens, including COVID-19 rapid testing solutions. More recently, they have pivoted strongly toward DNA data storage as a sustainable alternative to conventional digital archiving, securing significant EU funding to scale this technology.

What they specialise in

How they've shifted over time

Biosistemika began its H2020 journey in 2019 with a focus on bioinformatics and virome diagnostics — plant virus detection using NGS technologies. By 2020-2021, their work split in two directions: rapid COVID-19 diagnostics (responding to the pandemic) and DNA data storage, which quickly became their dominant investment. The trajectory is clear — from biological sequencing and diagnostics toward a bold bet on DNA as a medium for digital information storage.

Biosistemika is concentrating resources on DNA data storage as their flagship technology, suggesting future collaborations will center on sustainable digital archiving and synthetic biology applications.

How they like to work

Biosistemika operates as both a project leader and a specialist partner, splitting evenly between coordinator and participant roles. With 18 unique partners across 6 countries, they maintain a moderately diverse network for an SME of their size. Their progression from SME Instrument Phase 1 to Phase 2 as coordinator shows they are comfortable driving innovation agendas, while their participant roles in larger consortia (INEXTVIR, RAPID-COVID) demonstrate they can integrate into multi-partner research teams.

They have built a network of 18 partners across 6 European countries, spanning both academic training networks (MSCA) and applied health research consortia. For a 4-project SME, this is a well-diversified collaboration base.

What sets them apart

Biosistemika sits at a rare intersection: deep molecular biology expertise combined with an ambitious push into DNA data storage — a field with very few European SME players. Their diagnostic platform experience gives them practical know-how in sample handling, automation, and biological assay development that directly transfers to DNA storage workflows. For consortium builders, they offer a production-oriented biotech partner that bridges wet-lab biology with digital technology challenges.

Highlights from their portfolio

• DATANA
  Their largest project (EUR 1.87M, SME Instrument Phase 2) as coordinator, scaling DNA data storage technology — signals this is their core strategic bet.
• RAPID-COVID
  Pandemic-response project developing automated point-of-care COVID-19 diagnostics, demonstrating their ability to rapidly deploy molecular biology expertise to urgent health challenges.
• DNA DS
  SME Instrument Phase 1 feasibility study that laid the groundwork for the much larger DATANA project — shows a deliberate, staged commercialization strategy.